Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Cosentyx ™ (secukinumab) in Europe to treat ankylosing spondylitis (AS) and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results